共 50 条
- [41] Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysisJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (06) : 2345 - 2354Brown, Timothy J.Mamtani, RonacGimotty, Phyllis A.Karasic, Thomas B.Yang, Yu-Xiao
- [42] Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysisJournal of Cancer Research and Clinical Oncology, 2023, 149 : 2345 - 2354Timothy J. BrownRonac MamtaniPhyllis A. GimottyThomas B. KarasicYu-Xiao Yang
- [43] Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular CarcinomaADVANCES IN THERAPY, 2022, 39 (05) : 2165 - 2177Zhou, TingCao, YingdanWang, XintianYang, LanWang, ZijingMa, AixiaLi, Hongchao
- [44] Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular CarcinomaAdvances in Therapy, 2022, 39 : 2165 - 2177Ting ZhouYingdan CaoXintian WangLan YangZijing WangAixia MaHongchao Li
- [45] Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trialANNALS OF ONCOLOGY, 2023, 34 : S1535 - S1536Cheon, J.Ryoo, B-Y.Kim, H-D.Kim, K-P.Ryu, M. H.Chon, H. J.Kang, B.Finn, R. S.Yoo, C.
- [46] Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinomaFRONTIERS IN ONCOLOGY, 2023, 13Tseng, Chien-YuTsai, Yi-WenShiu, Ming-Neng
- [47] The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line LenvatinibONCOLOGY, 2023, 101 (08) : 491 - 501Chihiro, KikukawaKawaoka, TomokazuUchikawa, ShinsukeKinami, TakahiroYamasaki, ShintaroKosaka, MasanariJohira, YusukeYano, ShigekiAmioka, KeiNaruto, KensukeAndo, YuwaYamaoka, KenjiTeraoka, YujiUchida, TakuroFujino, HatsueNakahara, TakashiOno, AtsushiMurakami, EisukeOkamoto, WataruYamauchi, MasamiMiki, DaikiTsuge, MasatakaImamura, MichioAikata, HiroshiOka, Shiro
- [48] The efficacy of molecular targeted therapies after atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC) in JapanJOURNAL OF HEPATOLOGY, 2022, 77 : S379 - S379Tsuchiya, KaoruHayakawa, YukaYasui, YutakaKakegawa, TatsuyaHiguchi, MayuTakaura, KentaTanaka, ShoheiMaeyashiki, ChiakiKaneko, ShunTamaki, NobuharuNakanishi, HiroyukiKurosaki, MasayukiIzumi, Namiki
- [49] Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-AnalysisCANCERS, 2024, 16 (16)Peng, Tzu-RongWeng, Yi-FangWu, Ta-WeiWu, Chao-ChuanChou, Yi-ChunHsu, Ching-Sheng
- [50] Evaluation of first-line systemic treatments for unresectable hepatocellular carcinoma (uHCC): A network meta-analysisANNALS OF ONCOLOGY, 2020, 31 : S1310 - S1310Zhi, W.Xu, F.Luo, J.Zhang, C.Huang, X.Han, Y.